Comparison of semaglutide or dulaglutide versus empagliflozin for risk for death and cardiovascular outcomes among patients with type 2 diabetes : two target trial emulation studies
Saeed A, Mulukutla SR, Thoma F, et al.
Ann Intern Med. Pub. online 17 Jun 2025.
Leggi